Propanc Biopharma, Inc. (PPCB)
OTCMKTS · Delayed Price · Currency is USD
5.25
-0.25 (-4.55%)
Apr 4, 2025, 2:39 PM EST

Propanc Biopharma Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 2015 - 2019
Selling, General & Admin
0.951.291.531.731.583.31
Upgrade
Research & Development
0.230.250.250.260.230.18
Upgrade
Operating Expenses
1.181.541.781.991.813.49
Upgrade
Operating Income
-1.18-1.54-1.78-1.99-1.81-3.49
Upgrade
Interest Expense
-0.43-0.67-0.53-0.57-0.45-1.75
Upgrade
Interest & Investment Income
0000.0100
Upgrade
Currency Exchange Gain (Loss)
-0.070.020.01-0.040.03-0.14
Upgrade
Other Non Operating Income (Expenses)
0.030.18-0.53-0.1-0.010.44
Upgrade
EBT Excluding Unusual Items
-1.66-2-2.83-2.7-2.24-4.94
Upgrade
Other Unusual Items
-0.010.050.04-0.020.10.07
Upgrade
Pretax Income
-1.67-1.95-2.79-2.71-2.14-4.88
Upgrade
Income Tax Expense
-0-0.13-0.13-0.05-0.11-0.13
Upgrade
Net Income
-1.67-1.82-2.66-2.66-2.03-4.74
Upgrade
Preferred Dividends & Other Adjustments
0.190.190.470.70.39-
Upgrade
Net Income to Common
-1.86-2.01-3.13-3.36-2.42-4.74
Upgrade
Free Cash Flow
-0.6-0.94-1.11-1.44-1.15-1.85
Upgrade
EBITDA
-1.18-1.54-1.77-1.99-1.81-3.49
Upgrade
D&A For EBITDA
000000
Upgrade
EBIT
-1.18-1.54-1.78-1.99-1.81-3.49
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.